News

Profusa Strengthens European Market Presence with Angiopro Deal

Profusa Strengthens European Market Presence with Angiopro Deal

Profusa Expands its Market Reach in Europe

Profusa, Inc. (NASDAQ: PFSA), a leader in digital health technology, is thrilled to announce a significant enhancement to its commercial operations in Europe. By signing a letter of intent with Angiopro GmbH, a well-respected MedTech distributor, Profusa aims to broaden the reach of the Lumee Oxygen platform, which is designed for continuous biochemical monitoring.

Target Markets for the Lumee Platform

With its eyes set on specific initial markets, Profusa plans to introduce its innovative technology in Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia. This strategic move is expected to cover approximately 35% of the European Union's population, particularly in regions with a combined total of around 300,000 annual endovascular procedures.

Collaboration with Angiopro GmbH

The partnership with Angiopro is more than just a distributor agreement; it marks a collaboration focused on addressing clinical needs in vascular and peripheral diseases. Angiopro's CEO, Benjamin J. Rieck, expressed enthusiasm for this alliance, emphasizing the shared vision of utilizing the Lumee platform to create additional clinical solutions for chronic conditions, including diabetes and others.

Angiopro's Commitment to Innovation

Angiopro is committed to revolutionizing patient care through advanced cardiovascular technologies. With a solid foundation in interventional cardiology and vascular surgery, along with extensive networks and regulatory expertise, Angiopro is strategically positioned to propel Profusa's Lumee platform forward in the European market.

Profusa's Vision and Market Potential

Profusa is stepping confidently into this partnership armed with growth capital and an ambitious vision. Dr. Ben Hwang, the Chairman and CEO of Profusa, reiterated the company’s goal of delivering pioneering real-time personal healthcare technologies to clinicians. With a global market potential exceeding $10.5 billion for its tissue oxygen technology across multiple indications—spanning from peripheral artery disease to critical limb ischemia—Profusa is poised to make a significant impact.

Innovative Technology at Its Finest

The Lumee platform encompasses long-lasting, injectable biosensors designed to provide reliable and actionable medical-grade data. Profusa strives to empower individuals by offering a personalized biochemical signature that healthcare providers can trust, effectively enhancing patient outcomes.

The Future of Continuous Monitoring

As Profusa continues to develop its cutting-edge technology, the collaboration with Angiopro serves as a crucial stepping stone. This partnership not only signifies the expansion of their distributor network but also promises robust growth and innovation in the healthcare sector. By focusing on building infrastructure tailored to meet clinical needs, Profusa aims to solidify its role as a leader in digital health technologies.

Conclusion

In a rapidly evolving healthcare landscape, partnerships like the one between Profusa and Angiopro are vital. They pave the way for enhanced patient care and the adoption of advanced monitoring technologies that can transform how healthcare services are delivered across Europe.

Frequently Asked Questions

What is the Lumee Oxygen platform?

The Lumee Oxygen platform is a cutting-edge technology designed for continuous monitoring of an individual’s biochemistry, aiming to improve patient care.

Which markets is Profusa targeting for the Lumee platform?

Profusa is focusing on markets including Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavian countries.

Who is Angiopro?

Angiopro GmbH is a specialized MedTech distributor focusing on cardiovascular technologies that enhance patient care in Europe.

What is the market potential for Profusa’s technology?

Profusa's technology has an estimated global addressable market exceeding $10.5 billion across various medical indications.

How does this partnership benefit patients?

By enhancing access to innovative monitoring technologies, this partnership aims to improve clinical outcomes for patients with chronic conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Updated Category News Views 27

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

Continue Reading
Divorce Expertise: Obenhaus Adds CDFA Credential

Updated Category News Views 46

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Continue Reading
Veterans Find Community and Wellness at Orland Hills Bash

Updated Category News Views 16

A Celebration of Veterans and Community Orland Hills is set to light up with a unique Veterans Day Bash on November 1, 2026. This isn't just your run-of-the-mill community gathering; it's an event that brings together veterans from all around for a day packed with resources, education, and a chance to connect with kindred spirits—all thanks to the collaboration between...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Medicare Limits and Long-Term Care Planning Tips

Updated Category News Views 36

Grappling with Medicare's Gaps Most folks hear Medicare and feel a sigh of relief—thinking it's a catch-all net for healthcare in your golden years. But hold on, when it comes to long-term care, Medicare's got more holes than Swiss cheese. Cindy Couyoumjian from Cinergy Financial lays it out pretty clear: Medicare doesn't cover what it calls 'custodial care'—you know,...

Continue Reading
Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Updated Category News Views 70

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Continue Reading
Amy Johnson Steps Up as GDIT President Amid Shifts

Updated Category News Views 68

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 69

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Dimethylaminopropylamine Market Eyes $732M by 2035

Updated Category News Views 21

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 93

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading

Top 5 Most Recently Viewed Articles

Infosys and Sally Beauty Forge Groundbreaking IT Partnership

Updated Category News Views 165

Infosys has officially linked arms with Sally Beauty Holdings, Inc. to kick off a major IT transformation initiative. The aim? Ramp up enterprise-scale efficiencies through hyper-automation, putting Sally Beauty on the fast track for growth and keeping it competitive in a crowded beauty sector. You know how it goes when firms try to modernize—it's always a mixed bag,...

Continue Reading
HYLENR and TakeMe2Space Join Forces for Space Innovation

Updated Category News Views 324

HYLENR and TakeMe2Space Team Up for Space Exploration HYLENR Technologies, a frontrunner in clean energy solutions, has embarked on an exciting collaboration with the innovative space-tech company, TakeMe2Space. This partnership aims to explore the potential of Low-Energy Nuclear Reaction (LENR) technology for space-based computing infrastructures. Innovative...

Continue Reading
Convoy of Hope Sets Goal to Deliver Millions of Meals

Updated Category News Views 294

Convoy of Hope's Major Initiative to Support Families As families across America face difficulties in making ends meet, there's a growing need for assistance. For just $10, it's possible to provide 30 meals to those in need. Feeding Families Nationwide In response to the increasing needs of these families, Convoy of Hope has launched an impressive initiative to deliver 10...

Continue Reading
Transforming Diets: Pulses Market Growth and Insights

Updated Category News Views 207

The Flourishing Pulses Market Driven by Plant-Based Demand The global pulses market is experiencing significant growth, with projections estimating its value to rise from USD 78.0 billion in the coming years to USD 135.2 billion. This increase represents an impressive CAGR of 5.7% throughout the forecast period. The motivation behind this expansion is largely attributed...

Continue Reading
Understanding Windtree's New Istaroxime Patent for Heart Treatments

Updated Category News Views 123

Windtree's Istaroxime Patent Issuance: A Game Changer for Heart Failure Windtree Therapeutics, Inc., a pioneering biotech firm, recently celebrated a watershed moment with the issuance of a patent for istaroxime by the United States Patent and Trademark Office. This patent pertains to a unique intravenous formulation aimed at treating acute heart failure, an ailment that...

Continue Reading